Lessee, Operating Lease, Liability, to be Paid, Year Two of ENANTA PHARMACEUTICALS INC from 31 Dec 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
Summary
ENANTA PHARMACEUTICALS INC quarterly Lessee, Operating Lease, Liability, to be Paid, Year Two in USD history and change rate from 31 Dec 2019 to 30 Sep 2025.
  • ENANTA PHARMACEUTICALS INC Lessee, Operating Lease, Liability, to be Paid, Year Two for the quarter ending 30 Sep 2025 was $8,721,000, a 3% increase year-over-year.
Source SEC data
View on sec.gov
Lessee, Operating Lease, Liability, to be Paid, Year Two, Quarterly (USD)
Lessee, Operating Lease, Liability, to be Paid, Year Two, YoY Quarterly Change (%)

ENANTA PHARMACEUTICALS INC Quarterly Lessee, Operating Lease, Liability, to be Paid, Year Two (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $8,721,000 +$254,000 +3% 30 Sep 2025 10-K 19 Nov 2025 2025 FY
Q2 2025 $8,721,000 +$498,000 +6.1% 30 Jun 2025 10-Q 13 Aug 2025 2025 Q3
Q1 2025 $8,721,000 +$563,000 +6.9% 31 Mar 2025 10-Q 14 May 2025 2025 Q2
Q4 2024 $8,721,000 31 Dec 2024 10-Q 12 Feb 2025 2024 Q1
Q3 2024 $8,467,000 +$3,153,000 +59% 30 Sep 2024 10-K 27 Nov 2024 2024 FY
Q2 2024 $8,223,000 30 Jun 2024 10-Q 07 Aug 2024 2024 Q3
Q1 2024 $8,158,000 31 Mar 2024 10-Q 08 May 2024 2024 Q2
Q3 2023 $5,314,000 +$252,000 +5% 30 Sep 2023 10-K 22 Nov 2023 2023 FY
Q3 2022 $5,062,000 +$4,387,000 +650% 30 Sep 2022 10-K 23 Nov 2022 2022 FY
Q2 2022 $6,690,000 30 Jun 2022 10-Q 08 Aug 2022 2022 Q3
Q3 2021 $675,000 -$2,261,000 -77% 30 Sep 2021 10-K 24 Nov 2021 2021 FY
Q3 2020 $2,936,000 30 Sep 2020 10-K 25 Nov 2020 2020 FY
Q2 2020 $4,396,000 30 Jun 2020 10-Q 10 Aug 2020 2020 Q3
Q1 2020 $3,927,000 31 Mar 2020 10-Q 11 May 2020 2020 Q2
Q4 2019 $3,457,000 31 Dec 2019 10-Q 10 Feb 2020 2020 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.